AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

PEM, a Starting Point to Investigate ME/CFS

Recruitingn/aAges 18 Years - 65 YearsAllUniversity Medical Center Groningen
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Exercise is an important contributor to general health and is considered a potential remedy for chronic diseases. This is in strong contrast with the observation that in most myalgic encephalomyelitis (ME/CFS) patients exercise aggravates their symptoms. Recently, post-exertional malaise (PEM) is defined as the key symptom of ME/CFS. The etiology and pathophysiological mechanisms underlying ME/CFS are still unknown and objective diagnostic criteria are not available. Various hypotheses are postulated including disorders of several organ systems but the heterogenous presentation of symptoms in patients, and the multisystem deficits complicate reaching an all-encompassing hypothesis. It seems therefore reasonable to focus on the key symptom, i.e., PEM. PEM can be induced by minor cognitive or physical exertion and can be assessed with questionnaires. Acute physical activity triggers comple

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Willing and be able to complete all study procedures * Able to provide informed consent Additional inclusion criteria for ME/CFS patients * ME/CFS patients have to meet the criteria of the ICC OR CCC. * A self-reported illness narrative of the development of persistent fatigue and post-exertional malaise according to the DSQ-2. The persistent fatigue may have an acute onset or become progressively worse over 6 months. Exclusion Criteria: * Use of immune-modulating drugs in the past 3 months. * A serious medical condition that may explain symptoms similar to ME/CFS, such as cancer, coronary artery disease, uncontrolled diabetes, chronic infection (hepatitis B and C, tuberculosis, HIV), inflammatory diseases, autoimmune diseases (e.g. such as rheumatoid arthritis, lupus or polymyositis), severe COPD or other severe persistent respiratory disease, severe anemia, renal failure, Addison's or Cushing's disease or severe neurological disease (such as Parkinson's disease). * History of head injury with loss of consciousness or amnesia lasting greater than a few seconds within last five years or lasting greater than 5 minutes at any point during their lifetime. Persons with medical record evidence of post-concussive symptoms lasting more than six months are also excluded. * Suspected, probable, or confirmed Lyme disease * Current or substance use disorder within last 5 years * A mood disorder or other psychiatric diagnosis prior to a diagnosis of ME/CFS. * Pregnant, actively seeking to become or breastfeeding in the past 12 months. * BMI \>35. * having cognitive or communication problems which reduces the capacity to understand instructions. * planned a change in medication during the testing period. * Use of medication that affects the blood pressure (e.g. Beta-blockers, fludrocortisone, vasoconstrictors). * Participation in a clinical protocol (e.g. anti-inflammatory drug intervention study) which includes an intervention that may affect the results of the current study. * Claustrophobia * Current (within 1 week) use of prescription or over-the-counter medications, herbal supplements, or nutraceuticals that may influence brain excitability that the potential participant is either unwilling or clinically unable to safely wean off for the duration of the period of the visits. The possibility for a potential participant to be weaned off medication will be cooperatively determined by both the clinical investigative team and personal physicians. Examples of medications that influence brain excitability include tricyclic antidepressants, hypnotic, antiepileptic, antipsychotic medication, stimulants, antihistamines, muscle relaxants, dopaminergic medications, and sleep medications. * Use of B12 high dosage injections * Being colorblind Additional exclusion criteria for control subjects: * performing high intensity or moderate intensity activities more than 30 minutes per week * substantial fatigue as determined using MFIS fatigue questionnaire \>30
๐Ÿ’Š

What it tests

  • No intervention is planned
๐Ÿ“

Where

1 site
UMC Groningen
Groningen, Netherlands
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy